Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.

Journal of cellular physiology - 1 Oct 2020

Thomas Joseph M, Wang Xiaobo, Guo Gongbo, Li Tianxia, Dai Bingling, Nucifora Leslie G, Nucifora Frederick C, Liu Zhaohui, Xue Fengtian, Liu Chunfeng, Ross Christopher A, Smith Wanli W

Abstract excerpt

Parkinson's disease (PD) is one of the most common movement disorders with loss of dopaminergic neurons and the presence of Lewy bodies in certain brain areas. However, it is not clear how Lewy body (inclusion with protein aggregation) formation occurs. Mutations in leucine-rich repeat kinase 2 (LRRK2) can cause a genetic form of PD and contribute to sporadic PD with the typical Lewy body pathology. Here, we used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Guanosine Triphosphate
Share to Inclusion Bodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Lewy Bodies

Share to Mutant Proteins

Share to Parkinson Disease

Share to Protein Aggregation, Pathological

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 32180220
DOI: 10.1002/jcp.29632
PMCID: PMC7473462

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.PMID 32180220Read ↗

Leucine‐rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule‐associated protein 1B to ameliorate lysosomal dysfunction and parkinsonismSemantic proximity Read ↗

LRRK2 and Proteostasis in Parkinson's Disease.Semantic proximity Read ↗

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.Semantic proximity Read ↗

Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.Semantic proximity Read ↗

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.Semantic proximity Read ↗

Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.Semantic proximity Read ↗

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.Semantic proximity Read ↗

Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

LRRK2 Parkinson disease mutations enhance its microtubule association.Semantic proximity Read ↗

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.